Invivyd reported substantial doubt about continuing as a going concern after a $119.3 million net loss. PEMGARDA’s EUA is set to terminate on June 29, 2027; positive interim results could support a VYD2311 BLA submission.
IVVD · Invivyd, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, we will not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 44%
- Last earnings
- Sep 29, 2026
- Latest filing
- 10-Q · Nov 16
- Price history
- Aug 2021 to Nov 2026
Up next
Latest documents
Invivyd said DECLARATION interim analysis data are expected imminently after discussions with the FDA. Q3 2026 PEMGARDA net product revenue rose 18% to $15.4 million, cash and cash equivalents were $126.4 million, and net loss was $33.5 million.
Invivyd said VYD2311 met all LIBERTY primary and secondary endpoints and showed superior safety and tolerability versus an mRNA COVID-19 vaccine; DECLARATION safety and immunogenicity data are expected in October 2026 to support a planned FDA BLA via Accelerated Approval.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Early-stage programs | $835K | three months ended September 30, 2026 filing | +718.6% |
|
|
|||
| Pemivibart | $212K | three months ended September 30, 2026 filing | -36.3% |
|
|
|||
| VBY329 | $8K | three months ended September 30, 2026 filing | — |
| VMS063 | $1.05M | three months ended September 30, 2026 filing | — |
| VYD2311 | $8.35M | three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IVVD
this stock
Invivyd, Inc.
|
$122.01M | -83.3% | +110.5% | — | 12.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 21
Invivyd said DECLARATION interim analysis data are expected imminently after discussions with the FDA. Q3 2026 PEMGARDA net product revenue rose 18% to $15.4 million, cash and cash equivalents were $126.4 million, and net loss was $33.5 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IVVD | -29.1% | -32.7% | -63.8% | -29.1% | -83.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -20.5% | -23.5% | -54.6% | -20.3% | -84.5% |